Patents by Inventor Ulhas Dhuppad

Ulhas Dhuppad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210196631
    Abstract: The present invention relates to a pharmaceutical foam composition comprising a corticosteroid and a Vitamin D analogue for topical administration to a patient in need thereof, such as for the treatment of plaque psoriasis. The present invention also relates to a process for preparing the composition and a suitable container system for administration of the composition. Preferably, the invention relates to the topical administration of betamethasone dipropionate and calcipotriene with one or more pharmaceutically acceptable excipients and propellants where the composition is stable in the container system coated with a coating material selected from the group comprising of epoxyphenol resin, modified polyesters, microflex coating or polyacrylates.
    Type: Application
    Filed: August 27, 2019
    Publication date: July 1, 2021
    Inventors: Ulhas Dhuppad, Sushrut Kulkarni, Madhusudhan Bommagani, Roopali Amoi Oravkar, Ranjith Kumar Mamidala, Bhanudas Yadav Shalke
  • Patent number: 10709663
    Abstract: The present invention relates to a mupirocin topical pharmaceutical composition in a pump device, and its use for dispensing predetermined quantities of mupirocin for treating skin lesions.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: July 14, 2020
    Assignee: GLENMARK PHARMACEUTICALS, INC., USA
    Inventors: Ulhas Dhuppad, A. V. V. P. S. Raghuveer, Ram Reddy Patlolla, Atul Chopade, Madhusudhan Bommagani, Rahul Kapse, Sushrut Kulkarni
  • Publication number: 20200215051
    Abstract: This disclosure relates to a nebulization composition comprising tiotropium, or a pharmaceutically acceptable salt thereof, and indacaterol, or a pharmaceutically acceptable salt thereof. This disclosure also relates to a process for preparing such a composition and to methods of treating inflammatory and/or obstructive airway diseases using such a composition.
    Type: Application
    Filed: January 2, 2020
    Publication date: July 9, 2020
    Inventors: Sushrut Kulkarni, Sunil Chaudhari, Suresh Rajurkar, Chetan Yewale, Rajesh Ankam, Ulhas Dhuppad
  • Publication number: 20190275269
    Abstract: The present invention relates to a dry powder inhaler for administering a medicament via oral inhalation route to a subject. Particularly, the dry powder inhaler according to present invention is suitable for delivering accurate doses of a medicament in different ranges of inspiratory capacity of the subject.
    Type: Application
    Filed: May 23, 2019
    Publication date: September 12, 2019
    Applicant: GLENMARK PHARMACEUTICALS LIMITED
    Inventors: Ulhas DHUPPAD, Rachel Rachel STRIEBIG, Scott Alexander LEWIS, Matthew David ALLEN, Lai Chiu TANG, Stuart Robert ABERCROMBIE, John William Sanford HALE, Thomas Stephen COLLINGS
  • Publication number: 20190224119
    Abstract: The present invention relates to a mupirocin topical pharmaceutical composition in a pump device, and its use for dispensing predetermined quantities of mupirocin for treating skin lesions.
    Type: Application
    Filed: March 13, 2019
    Publication date: July 25, 2019
    Inventors: Ulhas Dhuppad, A.V.V.P.S. Raghuveer, Ram Reddy Patlolla, Atul Chopade, Madhusudhan Bommagani, Rahul Kapse, Sushrut Kulkarni
  • Patent number: 10357622
    Abstract: The present invention relates to a dry powder inhaler for administering a medicament via oral inhalation route to a subject. Particularly, the dry powder inhaler according to present invention is suitable for delivering accurate doses of a medicament in different ranges of inspiratory capacity of the subject.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: July 23, 2019
    Assignee: GLENMARK PHARMACEUTICALS LIMITED
    Inventors: Ulhas Dhuppad, Rachel Victoria Striebig, Scott Alexander Lewis, Matthew David Allen, Lai Chiu Tang, Stuart Robert Abercrombie, John William Sanford Hale, Thomas Stephen Collings
  • Patent number: 9987260
    Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: June 5, 2018
    Assignee: GLENMARK SPECIALTY S.A.
    Inventors: Ulhas Dhuppad, Franciscus Koppenhagen, Sunil Chaudhari, Suresh Rajurkar, Chandrakant Dhatrak, Alkesh Kasliwal
  • Publication number: 20170326117
    Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.
    Type: Application
    Filed: July 28, 2017
    Publication date: November 16, 2017
    Inventors: Ulhas DHUPPAD, Franciscus KOPPENHAGEN, Sunil CHAUDHARI, Suresh RAJURKAR, Chandrakant DHATRAK, Alkesh KASLIWAL
  • Patent number: 9757365
    Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: September 12, 2017
    Assignee: Glenmark Specialty S.A.
    Inventors: Ulhas Dhuppad, Franciscus Koppenhagen, Sunil Chaudhari, Suresh Rajurkar, Chandrakant Dhatrak, Alkesh Kasliwal
  • Publication number: 20160339003
    Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.
    Type: Application
    Filed: May 17, 2016
    Publication date: November 24, 2016
    Inventors: Ulhas DHUPPAD, Franciscus KOPPENHAGEN, Sunil CHAUDHARI, Suresh RAJURKAR, Chandrakant DHATRAK, Alkesh KASLIWAL
  • Publication number: 20160310410
    Abstract: Described herein is a fixed dose pharmaceutical composition containing arformoterol or its salt and a glycopyrronium salt. Particularly, a fixed dose pharmaceutical composition in the form of an aerosol or an aerosolizable for inhalation administration includes arformoterol or its salt, a glycopyrronium salt, and pharmaceutically acceptable excipients. Also described is a process for preparing the compositions and their use for the treatment of asthma and/or chronic obstructive pulmonary disease in a subject in need thereof. Also described are pharmaceutical compositions that include an effective amount of arformoterol (or its salt), a glycopyrronium salt or their combination in the form of a suspension or solution, and methods of their preparation.
    Type: Application
    Filed: April 25, 2016
    Publication date: October 27, 2016
    Inventors: Ulhas Dhuppad, Franciscus KOPPENHAGEN, Ashok KATKURWAR, Ramakant CHANAGARE, Kautik SHIROLE, Jitendra PATIL, Rajesh ANKAM, Nainesh PATEL
  • Publication number: 20150297523
    Abstract: The present invention relates to a pre-lyophilized composition comprising bendamustine or its pharmaceutically acceptable salt, a pharmaceutically acceptable carrier, an organic solvent and water. Furthermore, the present invention provides a stable pharmaceutical composition comprising bendamustine hydrochloride prepared from such pre-lyophilized composition, a process for preparing such composition; and its use in the treatment of cancer.
    Type: Application
    Filed: May 30, 2014
    Publication date: October 22, 2015
    Applicant: Glenmark Pharmaceuticals Limited
    Inventors: Ulhas Dhuppad, Dattatray Patil
  • Patent number: 9078923
    Abstract: The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: July 14, 2015
    Assignee: GLENMARK PHARMACEUTICALS LIMITED
    Inventors: Ulhas Dhuppad, Ashok Katkurwar, Yashwant Gupta, Rajesh Ankam, Chandrakant Dhatrak
  • Publication number: 20150174346
    Abstract: The present invention relates to a dry powder inhaler for administering a medicament via oral inhalation route to a subject. Particularly, the dry powder inhaler according to present invention is suitable for delivering accurate doses of a medicament in different ranges of inspiratory capacity of the subject.
    Type: Application
    Filed: December 23, 2014
    Publication date: June 25, 2015
    Inventors: Ulhas DHUPPAD, Rachel Victoria STRIEBIG, Scott Alexander LEWIS, Matthew David ALLEN, Lai Chiu TANG, Stuart Robert ABERCROMBIE, John William Sanford HALE, Thomas Stephen COLLINGS
  • Publication number: 20150079178
    Abstract: The present invention relates to a stable fixed dose aqueous pharmaceutical composition (e.g., contained in a container) for nasal administration to a human, comprising mometasone or its salt, olopatadine or its salt. The composition may further include a hydrocolloid. The invention also relates to a process for preparing the pharmaceutical composition, and the use of the pharmaceutical composition in the treatment of rhinitis in a subject.
    Type: Application
    Filed: September 11, 2014
    Publication date: March 19, 2015
    Inventors: Ulhas DHUPPAD, Ashok Katkurwar, Yashwant Gupta, Rajesh Ankam, Chandrakant Dhatrak
  • Publication number: 20130203778
    Abstract: The present patent application relates to a pharmaceutical composition comprising a fused pyrimidineone derivative having transient receptor potential modulating activity and a hydrophilic carrier.
    Type: Application
    Filed: March 21, 2011
    Publication date: August 8, 2013
    Applicant: Glenmark Pharmaceuticals S.A.
    Inventors: Ulhas Dhuppad, Sunil Chaudhari
  • Patent number: 8404727
    Abstract: The present patent application relates to a pharmaceutical composition for oral administration that includes a certain pyrrolidine derivative as DPP-IV inhibitor, and a pharmaceutically acceptable excipient. More particularly, the present invention contemplates pharmaceutical compositions that include melogliptin and a pharmaceutically acceptable excipient as well as to processes for preparing the pharmaceutical composition and the use of the composition in reducing glucose level in a subject. The present invention also contemplates an impurity associated with melogliptin.
    Type: Grant
    Filed: January 7, 2010
    Date of Patent: March 26, 2013
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Ulhas Dhuppad, Vaijnath Aravat, Someshwar Navhat, Abraham Thomas, Suresh Kadam
  • Publication number: 20130028977
    Abstract: The present invention relates to a pharmaceutical powder composition for inhalation comprising an active ingredient and a pharmaceutically acceptable carrier, process for preparing such composition, and its use for the treatment of respiratory disorder in a subject.
    Type: Application
    Filed: March 30, 2011
    Publication date: January 31, 2013
    Applicant: GLENMARK PHARMACEUTICALS LIMITED
    Inventors: Ulhas Dhuppad, Sunil Sudhakar Chaudhari
  • Publication number: 20110160213
    Abstract: The present invention relates to the pharmaceutical compositions, more particularly to the pharmaceutical compositions comprising novel phosphodiesterase type 4 (PDE4) inhibitors, and their use in treating allergic and inflammatory disorders.
    Type: Application
    Filed: January 31, 2008
    Publication date: June 30, 2011
    Applicant: Glenmark Pharmaceuticals, S.A.
    Inventors: Ulhas Dhuppad, Ganga Srinivas Arra
  • Publication number: 20100173964
    Abstract: The present patent application relates to a pharmaceutical composition for oral administration that includes a certain pyrrolidine derivative as DPP-IV inhibitor, and a pharmaceutically acceptable excipient. More particularly, the present invention contemplates pharmaceutical compositions that include melogliptin and a pharmaceutically acceptable excipient as well as to processes for preparing the pharmaceutical composition and the use of the composition in reducing glucose level in a subject. The present invention also contemplates an impurity associated with melogliptin.
    Type: Application
    Filed: January 7, 2010
    Publication date: July 8, 2010
    Applicant: Glenmark Pharmaceuticals S.A.
    Inventors: Ulhas DHUPPAD, Vaijnath Aravat, Someshwar Navhat, Abraham Thomas, Suresh Kadam